Literature DB >> 25327812

Effects of an Al(3+)- and Mg(2+)-containing antacid, ferrous sulfate, and calcium carbonate on the absorption of nemonoxacin (TG-873870) in healthy Chinese volunteers.

Yi-fan Zhang1, Xiao-jian Dai1, Ting Wang2, Xiao-yan Chen1, Li Liang2, Hua Qiao2, Cheng-yuan Tsai3, Li-wen Chang3, Ping-ting Huang3, Chiung-yuan Hsu3, Yu-ting Chang3, Chen-en Tsai3, Da-fang Zhong1.   

Abstract

AIM: To evaluate the effects of an Al(3+)- and Mg(2+)-containing antacid, ferrous sulfate, and calcium carbonate on the absorption of nemonoxacin in healthy humans.
METHODS: Two single-dose, open-label, randomized, crossover studies were conducted in 24 healthy male Chinese volunteers (12 per study). In Study 1, the subjects orally received nemonoxacin (500 mg) alone, or an antacid (containing 318 mg of Al(3+) and 496 mg of Mg(2+)) plus nemonoxacin administered 2 h before, concomitantly or 4 h after the antacid. In Study 2, the subjects orally received nemonoxacin (500 mg) alone, or nemonoxacin concomitantly with ferrous sulfate (containing 60 mg of Fe(2+)) or calcium carbonate (containing 600 mg of Ca(2+)).
RESULTS: Concomitant administration of nemonoxacin with the antacid significantly decreased the area under the concentration-time curve from time 0 to infinity (AUC0-∞) for nemonoxacin by 80.5%, the maximum concentration (Cmax) by 77.8%, and urine recovery (Ae) by 76.3%. Administration of nemonoxacin 4 h after the antacid decreased the AUC0-∞ for nemonoxacin by 58.0%, Cmax by 52.7%, and Ae by 57.7%. Administration of nemonoxacin 2 h before the antacid did not affect the absorption of nemonoxacin. Administration of nemonoxacin concomitantly with ferrous sulfate markedly decreased AUC0-∞ by 63.7%, Cmax by 57.0%, and Ae by 59.7%, while concomitant administration of nemonoxacin with calcium carbonate mildly decreased AUC0-∞ by 17.8%, Cmax by 14.3%, and Ae by 18.4%.
CONCLUSION: Metal ions, Al(3+), Mg(2+), and Fe(2+) markedly decreased the absorption of nemonoxacin in healthy Chinese males, whereas Ca(2+) had much weaker effects. To avoid the effects of Al(3+) and Mg(2+)-containing drugs, nemonoxacin should be administered ≥2 h before them.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25327812      PMCID: PMC4261130          DOI: 10.1038/aps.2014.95

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  20 in total

1.  Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.

Authors:  S Lober; S Ziege; M Rau; G Schreiber; A Mignot; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans.

Authors:  K Shiba; O Sakai; J Shimada; O Okazaki; H Aoki; H Hakusui
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

3.  Antacid interaction with new quinolones: dose regimen recommendations based on pharmacokinetic modeling of clinical data for ciprofloxacin, gatifloxacin and norfloxacin and metal cations.

Authors:  K Miyata; H Ohtani; M Tsujimoto; Y Sawada
Journal:  Int J Clin Pharmacol Ther       Date:  2007-01       Impact factor: 1.366

4.  In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.

Authors:  Heather J Adam; Nancy M Laing; C Richard King; Ben Lulashnyk; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

5.  Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.

Authors:  R E Polk; D P Healy; J Sahai; L Drwal; E Racht
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 6.  Review article: sleep and its relationship to gastro-oesophageal reflux.

Authors:  W C Orr; R Heading; L F Johnson; M Kryger
Journal:  Aliment Pharmacol Ther       Date:  2004-12       Impact factor: 8.171

7.  In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.

Authors:  Yen-Hsu Chen; Chia-Ying Liu; Jang-Jih Lu; Chi-Hsin R King; Po-Ren Hsueh
Journal:  J Antimicrob Chemother       Date:  2009-10-14       Impact factor: 5.790

Review 8.  Effect of sleep on gastroesophageal physiology and airway protective mechanisms.

Authors:  P Jay Pasricha
Journal:  Am J Med       Date:  2003-08-18       Impact factor: 4.965

Review 9.  Pharmacokinetic interactions related to the chemical structures of fluoroquinolones.

Authors:  Y Mizuki; I Fujiwara; T Yamaguchi
Journal:  J Antimicrob Chemother       Date:  1996-05       Impact factor: 5.790

10.  Coadministration of gatifloxacin and multivitamin preparation containing minerals: potential treatment failure in an elderly patient.

Authors:  Louise Mallet; Allen Huang
Journal:  Ann Pharmacother       Date:  2004-11-16       Impact factor: 3.154

View more
  1 in total

1.  Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers.

Authors:  Yi-Fan Zhang; Xiao-Jian Dai; Yong Yang; Xiao-Yan Chen; Ting Wang; Yun-Biao Tang; Cheng-Yuan Tsai; Li-Wen Chang; Yu-Ting Chang; Da-Fang Zhong
Journal:  Drug Des Devel Ther       Date:  2016-01-20       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.